Zacks Investment ResearchFri, 22 May 2026 17:15:26 GMTDenali Stock Dips as Biogen-Partnered Parkinson's Disease Study FailsBIIB+2.26%
MarketBeatFri, 22 May 2026 11:50:33 GMTBiogen Stock Slides After Trial Miss, But Analysts Stay BullishBIIB+2.26%
Seeking AlphaFri, 15 May 2026 15:10:59 GMTBiogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment OpportunityBIIB+2.26%
MarketBeatThu, 14 May 2026 23:10:47 GMTBiogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology PushBIIB+2.26%
CNBCThu, 14 May 2026 16:10:48 GMTBiogen advances Alzheimer's drug to late-stage trial despite disappointing dataBIIB+2.26%
BarronsThu, 14 May 2026 13:07:00 GMTBiogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.BIIB+2.26%
Seeking AlphaWed, 13 May 2026 21:10:50 GMTBiogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 TranscriptBIIB+2.26%
BenzingaThu, 30 Apr 2026 15:57:06 GMTBiogen Analysts Boost Their Forecasts Following Upbeat Q1 EarningsBIIB+2.26%
Seeking AlphaWed, 29 Apr 2026 18:21:41 GMTBiogen Inc. (BIIB) Q1 2026 Earnings Call TranscriptBIIB+2.26%
Zacks Investment ResearchWed, 29 Apr 2026 12:10:48 GMTBiogen Inc. (BIIB) Tops Q1 Earnings and Revenue EstimatesBIIB+2.26%
Investors Business DailyWed, 29 Apr 2026 10:00:46 GMTBiogen Walloped Wall Street's First Quarter Views; Here's What HappenedBIIB+2.26%
Zacks Investment ResearchFri, 24 Apr 2026 14:06:19 GMTBiogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?BIIB+2.26%
Zacks Investment ResearchWed, 22 Apr 2026 15:01:29 GMTEarnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to DeclineBIIB+2.26%
24/7 Wall StreetWed, 22 Apr 2026 14:27:53 GMTUBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?BIIB+2.26%
Zacks Investment ResearchTue, 21 Apr 2026 16:56:14 GMTBIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock UpBIIB+2.26%
24/7 Wall StreetMon, 20 Apr 2026 15:26:39 GMTWells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act?BIIB+2.26%
Zacks Investment ResearchFri, 17 Apr 2026 14:41:33 GMTShould Value Investors Buy Biogen (BIIB) Stock?BIIB+2.26%
Zacks Investment ResearchThu, 16 Apr 2026 13:06:08 GMT3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time HighBIIB+2.26%
The Motley FoolThu, 16 Apr 2026 09:30:00 GMTThis Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?BIIB+2.26%
